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EXTH-04. BLOCKADE OF NRF2/GLUTATHIONE METABOLISM 
AS A SYNTHETIC LETHALITY APPROACH FOR IDH1-MUTATED 
GLIOMA
Yang Liu1, Yanxin Lu2, Orieta Celiku2, Aiguo Li2, and Chunzhang Yang2; 
1National Cancer Institute, Rockville, MD, USA, 2National Cancer 
Institute, Bethesda, MD, USA
BACKGROUND: Mutations in isocitrate dehydrogenase (IDH1/2) are 
frequent genetic abnormalities in human malignancies. IDH1/2-mutated 
cancers are a recently defined disease entity with distinctive patterns of tumor 
cell biology, metabolism and resistance to therapy. Molecular targeting ap-
proaches against this disease cluster remain limited.   METHODS: We in-
vestigated the redox homeostasis in IDH1 mutant-transduced cells and 
patient-derived brain tumor initiating cells. The importance of antioxidant 
genes was confirmed through COX regression analysis on a large cohort of 
lower grade glioma. We investigated the biologic impact of Nuclear factor 
erythroid 2-related factor 2 (NRF2) on the glutathione de novo synthesis 
in IDH1-mutated cells. Finally, we evaluated the value of targeting NRF2/
glutathione metabolic pathway as a potential synthetic lethality approach 
for IDH1-mutated cell in vitro and in vivo.  RESULTS: We discovered that 
acquisition of cancer-associated IDH1 mutants results in constitutive acti-
vation of NRF2-governed cytoprotective pathways through decoupling of 
NRF2 from its E3 ligase Kelch-like ECH-associated protein 1. NRF2 medi-
ated the transcriptional activation of GCLC, GCLM and SLC7A11, which 
strengthens the glutathione de novo synthesis, and relieves the metabolic 
burden derived from IDH1 mutant neomorphic activity. Blockade of the 
NRF2/glutathione metabolic pathway synergizes with the elevated intrinsic 
reactive oxygen species, which results in overwhelming oxidative damage in 
IDH1-mutated cells, as well as a substantial reduction in tumor cell prolifer-
ation and xenograft expansion.  CONCLUSION: Our findings suggest that 
blockade of the NRF2/glutathione synthetic pathway is a novel targeting 
strategy for IDH1-mutated malignancies.
EXTH-05. THERAPEUTIC IMPLICATIONS OF TTFIELDS 
INDUCED DNA DAMAGE AND REPLICATION STRESS IN NOVEL 
COMBINATIONS FOR CANCER TREATMENT
Narasimha Kumar Karanam, Lianghao Ding, Asaithamby Aroumougame, 
and Michael Story; UT Southwestern Medical Center, Dallas, TX, USA
TTFields are low-intensity, intermediate frequency, alternating elec-
tric fields which are applied to tumor regions using non-invasive arrays. 
TTFields is approved for the treatment of glioblastoma and mesothelioma 
with clinical trials ongoing in other cancer types. The mechanism of ac-
tion for TTFields includes interference with mitosis, reduced DNA double 
strand break (DSB) repair capacity and the frank induction of DNA 
DSBs. The mechanism by which TTFields induces DNA DSBs appears to 
be through the enhancement of DNA replication stress with continued 
TTFields exposure. The induction of DNA DSBs appears to be as a result 
of significantly reduced expression of the DNA replication complex genes 
MCM6 and MCM10 as well as the Fanconi’s Anemia (FA) pathway genes. 
TTFields treatment increases the number of RPA foci, decreases nascent 
DNA length and increases R-loop formation which are markers of DNA 
replication stress. These results suggest that TTFields-induced replication 
stress is the underlying mechanism and cellular endogenous source of DNA 
DSB generation via replication fork collapse. The current study suggests 
that TTFields exposure causes a conditional vulnerability environment 
that renders cells more susceptible to chemotherapeutic agents that induce 
DNA damage and/or cause replication stress. Supporting this is the syner-
gistic cell killing seen with TTFields exposure concomitant with cisplatin, 
TTFields plus concomitant PARP inhibition with or without subsequent 
radiation, or radiation given at the completion of a TTFields exposure. Fi-
nally, TTFields-induced mitotic aberrations and DNA damage/replication 
stress events, although intimately linked to one another as one can expose 
the other, are likely initiated independently of one another as suggested by 
the gene expression analysis of 47 key mitosis regulator genes. These results 
establish that enhanced replication stress and reduced DNA repair capacity 
are also major mechanisms of TTFields effects, effects for which there are 
therapeutic implications.
EXTH-06. DOWN-REGULATION OF PD-L1 VIA FKBP5 LOWERED 
BY A CYCLOOXYGENASE-2 INHIBITOR IN GSCs AND GBM CELLS 
MAY BE ATTRIBUTABLE TO ENHANCE ANTITUMOR EFFECTS OF 
IMMUNOTHERAPY
Izumi Yamaguchi, Kohei Nakajima, Kenji Shono, Yoshifumi Mizobuchi, 
Toshitaka Fujihara, Keiko Kitazato, and Yasushi Takagi; Tokushima 
University Graduate School of Biomedical Sciences, Tokushima, Japan
BACKGROUND: Antitumor therapies targeting programmed cell 
death-1 (PD-1)/its ligand-1 (PD-L1) are influential at present stage. How-
ever, in glioblastoma (GBM), the expression of PD-L1 is variable and the 
role of anti-PD-1 antibody therapy is still unclear. The high expression 
of PD-L1 affects cell proliferation and invasion in GBM cells. As COX-2 
modulates PD-L1 expression in cancer cells, we tested our hypothesis that 
a COX-2 inhibitor, celecoxib may play a role on anti-PD-1 antibody treat-
ment via down-regulation of PD-L1.   METHODS: Six weeks old male 
C57BL/6 mice subjected to intracranial injection of mice glioma stem cells 
(GSCs) were randomly divided into four treatment groups; vehicle control 
(VC), celecoxib, anti PD-1 antibody or the combination of celecoxib and 
anti-PD-1 antibody groups and examined antitumor effects. To verify the 
mechanisms underlying antitumor effects, mice GSCs and human GBM cells 
were used.   RESULTS: Compared to each single treatment in the glioma 
model, the combination therapy of anti PD-1 antibody and celecoxib signifi-
cantly decreased the tumor volume and improved the survival period. Im-
portantly, the high expression of PD-L1 in the glioma model, mice GSCs and 
human GBM cells was decreased by celecoxib. Interestingly, the reduction of 
PD-L1 was associated with post-transcriptional regulation of co-chaperone 
FK506-binding protein 5 (FKBP5) by celecoxib. The combination therapy of 
anti PD-1 antibody with celecoxib could be a promising therapeutic strategy 
targeting PD-L1 in GSCs and GBM.   CONCLUSIONS: Down-regulation 
of PD-L1 via FKBP5 by celecoxib may play a role on the antitumor effects 
under the overwhelmed expression of PD-L1.
EXTH-07. OPTIMIZATION OF TARGETING ELTD1 IN 
GLIOBLASTOMA USING A MOLECULAR TARGETING APPROACH
Nataliya Smith, Debra Sauders, Rheal Towner, and Michelle Zalles; 
Oklahoma Medical Research Foundation, Oklahoma City, OK, USA
The standard of care for glioblastoma multiform (GBM), an aggressive 
form of cancer, has not significantly increased the prognosis for patients. 
ELTD1 (epidermal growth factor, latrophilin, and 7 transmembrane domain 
containing protein 1), a biomarker for angiogenesis, was found to be highly 
expressed in human high-grade gliomas. Novel treatments targeting ELTD1 
with polyclonal (pAb) and monoclonal (mAb) antibodies were effective as a 
potential cancer therapy in a G55-xenograft mouse model. While our studies 
have demonstrated that the blood brain barrier (BBB) was leaky around 
the tumor region, other studies have shown that the BBB is not equally dis-
rupted in GBM patients, therefore suggesting that the mAb may have diffi-
culty crossing the BBB and infiltrating the tumor due to its size. To overcome 
these limitations, this study focused on the optimization of targeting ELTD1 
by using an optimized svFc antibody fragment derived from our mAb 
against ELTD1. Immunocompromised mice were intracerebrally injected 
with human-G55 cells. Morphological MRI was used to monitor and cal-
culate tumor volumes. Treatments using IgG, anti-ELDT1 mAb or fragment 
upon tumor detection. Vascular perfusion images were obtained to examine 
vascular alterations. Molecular targeting imaging (mtMRI) was conducted 
to assess the binding specificity of our antibodies against the tumor region. 
Targeting ELTD1 with varying antibodies (anti-ELTD1 mAb and scFv frag-
ment) resulted in increased survival and decreased tumor volumes in a G55 
xenograft GBM mouse model. Additionally, through the use of mtMRI, we 
determined altered levels of binding specificity against the tumor region 
using three different anti-ELTD1 attached probes (monoclonal and scFv 
fragment antibodies). Our data suggest that the optimization of an anti-
ELTD1 therapy could be used to better target angiogenesis in glioblastomas.
EXTH-08. REPLACEMENT OF MICROGLIA BY BRAIN-ENGRAFTED 
MACROPHAGES PREVENTS MEMORY DEFICITS AFTER 
THERAPEUTIC WHOLE-BRAIN IRRADIATION
Xi Feng1, Sonali Gupta2, David Chen2, Zoe Boosalis2, Sharon Liu3, 
Nalin Gupta4, and Susanna Rosi5; 1University of California, San Francisco, 
Department of Physical Therapy and Rehabilitation Science, Department 
of Neurological Surgery, San Francisco, CA, USA, 2University of California, 
San Francisco, San Francisco, CA, USA, 3University of California, San 
Francisco, Department of Neurological Surgery, San Francisco, CA, USA, 
4University of California, San Francisco, Department of Neurological 
Surgery, Department of Pediatrics, San Francisco, CA, USA, 5University 
of California, San Francisco, Department of Physical Therapy and 
Rehabilitation Science, San Francisco, CA, USA
Microglia have a distinct origin compared to blood circulating myeloid 
cells. Under normal physiological conditions, microglia are maintained by 
self-renewal, independent of hematopoietic progenitors. Following genetic 
or pharmacologic depletion, newborn microglia derive from the local re-
sidual pool and quickly repopulate the entire brain. The depletion of brain 
resident microglia during therapeutic whole-brain irradiation fully prevents 
irradiation-induced synaptic loss and recognition memory deficits but the 
mechanisms driving these protective effects are unknown. Here, we demon-
strate that after CSF-1R inhibitor-mediated microglia depletion and thera-
peutic whole-brain irradiation, circulating monocytes engraft into the brain 
and replace the microglia pool. These monocyte-derived brain-engrafted 
macrophages have reduced phagocytic activity compared to microglia from 
irradiated brains, but similar to locally repopulated microglia without brain 
irradiation. Transcriptome comparisons reveal that brain-engrafted macro-
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phages have both monocyte and embryonic microglia signatures. These re-
sults suggest that monocyte-derived brain-engrafted macrophages represent 
a novel therapeutic avenue for the treatment of brain radiotherapy-induced 
cognitive deficits.
EXTH-09. FIRST-IN-HUMAN DOSING CONSIDERATIONS OF 
A BISPECIFIC ANTIBODY FOR TREATING GLIOBLASTOMA
Teilo Schaller, Matthew Foster, Ivan Spasojevic, Patrick Gedeon, 
Luis Sanchez-Perez, and John Sampson; Duke University Medical Center, 
Durham, NC, USA
Current therapy for glioblastoma (GBM) is incapacitating and limited 
by non-specific toxicity to the surrounding brain. We have developed an 
immunotherapeutic approach that selectively targets GBM by redirecting 
the patients’ own T cells towards the tumor in an antigen-specific manner 
using a bispecific antibody. Our novel bispecific antibody (“BRITE”) binds 
GBM-specific surface marker EGFRvIII and the CD3 receptor on T cells, 
resulting in crosslinking and tumor-specific cell lysis. We previously showed 
in patient-derived and syngeneic murine glioma models, that treatment with 
BRITE leads to long-term survival in mice with glioblastoma. A pharma-
cokinetic analysis in a CD3 humanized mouse revealed that BRITE in 
plasma and whole blood has an initial half-life of ~8 minutes and a terminal 
half-life of ~2.5 hours. Given our preclinical success, we have initiated clin-
ical trial-enabling studies, including studies of BRITE toxicology and GMP 
manufacturing of drug product. A crucial consideration for our proposed 
Phase 1 dose escalation trial is the starting dose in humans. To this end, we 
utilized the FDA-recommended minimum anticipated biological effect level 
(MABEL) of BRITE – a holistic approach that considers all available in vitro 
and in vivo data – to calculate the first-in-human starting dose of BRITE.
EXTH-10. THE ACTIVATION AND SENSITIZATION OF 
GLIOBLASTOMA CELLS VIA COLD ATMOSPHERIC PLASMA 
TREATMENT
Jonathan Sherman, Dayun Yan, Eda Gjika, and Michael Keidar; George 
Washington University, Washington, DC, USA
BACKGROUND: Treatment of glioblastoma multiforme (GBM) con-
tinues to remain a challenge using conventional treatment. Through 
an in vitro study we assessed the efficacy of our novel cold atmospheric 
plasma technology (CAP) to sensitize GBM cells to temozolomide (TMZ).  
METHODS: The CAP jet is formed through the discharge (Pk-Pk: 5.8 kV) 
between a ring grounded cathode and a central anode and with He flow 
through a glass tube. The discharge process is driven by an AC high voltage 
(3.16 kV) with a frequency of 12.5 kHz. Human glioblastoma (U87MG) 
cells were cultured in DMEM supplemented by 1% (v/v) penicillin and 
streptomycin solution and 10% (v/v) FBS. CAP was delivered to U87 cells 
in a 96-well plate for 1 min in combination with 10 and 15 μM H2O2. 
The cell viability was measured by using the MTT assay. We then tested 
TMZ concentrations of 10 and 50 uM. Cell viability was monitored with 
the Cell Titer Glo 2.0. luminescent assay. All experiments were performed in 
triplicate and were independently repeated at least 3 times.  RESULTS: We 
identified an activation state of U87MG cells after the plasma treatment. 
This activation state resulted in GBM cells sensitized to reactive species iden-
tified by decreased cell viability after treatment with H2O2 as compared 
to the H2O2 treatment alone (p< 0.005). In addition, the plasma-activated 
cells were sensitized to TMZ. Cells treated with CAP in combination with 
TMZ displayed decreased cell viability at TMZ concentrations of (10 uM) 
(p< 0.05) and (50 uM) (p< 0.005) as compared to TMZ alone.  CONCLU-
SIONS: This study demonstrates the activation phenomenon on GBM cells 
via direct CAP treatment. Due to this activation, the GBM cells were sensi-
tized to both H2O2 and TMZ identified via decreased cell viability. Future 
work looks to assess this effect of cell activation/sensitization with chemo-
therapy plus radiation treatment.
EXTH-11. TREATMENT WITH DELTA-24-RGDOX OF 
SUBCUTANEOUS TUMORS RESULTS IN ABSCOPAL EFFECT 
ERADICATING INTRACRANIAL MELANOMAS
Hong Jiang1, Dong Ho Shin1, Teresa Nguyen1, Marta M. Alonso2, 
Frederick Lang1, Candelaria Gomez-Manzano1, and Juan Fueyo1; 1MD 
Anderson Cancer Center, Houston, TX, USA, 2Clinica Universidad de 
Navarra, Pamplona, Spain
Immune checkpoint blockade has revolutionized cancer therapy; how-
ever the therapeutic benefit is limited to only a subset of patients with im-
munogenic (“hot”) tumors and is compromised by immune-related adverse 
events. We have reported the efficacy of oncolytic adenovirus Delta-24-
RGDOX (DNX-2440) in syngeneic glioma mouse models. We hypothe-
sized that localized treatment with the virus is effective against disseminated 
melanomas, including intracranial melanomas. We tested the hypothesis 
in the subcutaneous (s.c.)/s.c. and s.c./intracranial (i.c.) melanoma models 
derived from luciferase-expressing B16-Red-FLuc cells in C57BL/6 mice. 
First, through monitoring tumor growth with bioluminescence imaging, we 
found that, in both s.c./s.c. and s.c./i.c. models, three injections of Delta-24-
RGDOX significantly inhibited the growth of both the virus-injected s.c. 
tumor and untreated distant s.c. or i.c. tumor, thereby prolonging survival. 
Next, through cell profiling with flow cytometry, we observed that the virus 
increased the presence of T cells and effector T cell frequency in the virus-
injected tumor and mediated the same changes in T cells from peripheral 
blood, tumor-draining lymph nodes (TDLNs), spleens, and brain hemi-
spheres with untreated tumor. Moreover, Delta-24-RGDOX decreased the 
frequency of exhausted T cells and regulatory T cells in the virus-injected 
and untreated i.c. tumors. Consequently, the virus promoted recruitment 
and/or in situ expansion of antigen-specific T cells in tumors expressing the 
target antigen. Therefore, we concluded that local intratumoral injection of 
Delta-24-RGDOX resulted in systemic immune activity against the dissem-
inated tumors. Furthermore, we speculate that given the immunogenicity, 
cancer-selectivity and intratumoral administration of the virus, Delta-24-
RGDOX is expected to have an improved safety profile when compared 
to immune checkpoint blockade treatment strategies. This is the first report 
demonstrating that local administration of oncolytic adenovirus results in 
eradication of intracranial tumors, suggesting Delta-24-RGDOX could be 
used to manage brain metastases of melanoma.
EXTH-12. RADIATION ENHANCES MELANOMA RESPONSE TO 
IMMUNOTHERAPY AND SYNERGIZES WITH BENZODIAZEPINES 
TO PROMOTE ANTI-TUMOR ACTIVITY
Daniel Pomeranz Krummel1, Tahseen Nasti2, Benjamin Izar3, Maxwell Xu4, 
Lindsey Lowder5, Robert Press5, Milota Kaluzova5, Laura Kallay1, 
Manali Rupji5, Andre Burnham2, Guanguan Li6, Taukir Ahmed7,  
Havi Rosen5, Erin Connolly2, Havva Keskin5, Midhun Ben Thomas5, 
Walter Curran8, Ragini Kudchadkar5, Brent Weinberg9, Jeffrey Olson5, 
Matthew Schniederjan5, Stewart Neil5, Jing Su10, David Lawson5, 
James Cook6, Andrew Jenkins5, Jeanne Kowalski11, Mohammad Khan5, 
and Soma Sengupta12; 1University of Cincinnati, Cincinnati, OH, USA, 
2Emory University, Atlanta, USA, 3Dana-Farber, Boston, MA, USA, 4Johns 
Hopkins University, Baltimore, MD, USA, 5Emory University, Atlanta, GA, 
USA, 6University Wisconsin, Milwaukee, WI, USA, 7Emory University, 
Milwaukee, WI, USA, 8Winship Cancer Institute of Emory University, 
Atlanta, GA, USA, 9Emory University School of Medicine, Atlanta, GA, 
USA, 10Wake Forest School of Medicine, Winston-Salem, NC, USA, 11Dell 
Medical School, Austin, TX, USA, 12University of Cincinnati College of 
Medicine; Gardner Neuroscience Institute, Cincinnati, OH, USA
Melanoma brain metastases (MBM) occur in ~50% of advanced mel-
anoma patients. It is unclear if systemic therapies synergize with radio-
therapy (RT) and what the impact of RT timing has on efficacy. We find 
that RT followed by ICI (immune checkpoint inhibitors) (RTàICI) improves 
MBM patient survival compared to other combination strategies, also 
shown here in a murine melanoma model. RNA-seq of MBM tumors in 
the RTàICI group exhibit overrepresentation of genes implicated in NFKB 
signaling. There is also expression of GABAA receptor subunits across both 
treatment groups. We show that melanoma cells express functional GABAA 
receptors and that benzodiazepines impair tumor growth. Combination of 
sub-lethal RT doses with benzodiazepine results in significant ipsilateral and 
out of field abscopal anti-tumor activity, which is associated with enhanced 
tumor infiltration with poly-functional CD8 T-cells. This study provides evi-
dence that RT enhances MBM response to ICI and synergizes with benzodi-
azepines to promote anti-tumor activity.
EXTH-13. NEUROSURGICAL DELIVERY OF THE POLY ADP 
RIBOSE POLYMERASE-1 INHIBITOR OLAPARIB FROM 
A THERMO-RESPONSIVE BIODEGRADABLE PASTE POTENTIATES 
RADIOTHERAPY AND PROLONGS SURVIVAL IN HIGH-GRADE 
GLIOMA
Stuart Smith1, Riccardo Serra2, Jonathan Rowlinson1, Noah Gorelick2, 
Gareth Veal3, Kevin Shakesheff1, Henry Brem2, Richard Grundy1, 
Betty Tyler2, and Ruman Rahman1; 1University of Nottingham, 
Nottingham, United Kingdom, 2Johns Hopkins University, Baltimore, MD, 
USA, 3Newcastle University, Newcastle, United Kingdom
There has been considerable interest in repurposing the poly ADP ribose 
polymerase inhibitor and purported radiosensitiser olaparib (Lynparza), 
with a recent dose escalation study of olaparib plus temozolomide in re-
current GBM showing good tolerance (Fulton et al 2018). Due to systemic 
therapy-associated caveats such as dose-limiting toxicities and blood-brain-
barrier penetration, here we assess localised post-surgical delivery of olaparib 
from our previously developed poly(DL-lactic-co-glycolic acid) (PLGA) and 
poly(ethylene glycol) (PEG) (PLGA/PEG) thermo-sensitive biodegradable 
paste. Metabolic and clonogenic assays revealed impaired proliferation 
and clonal growth respectively, upon acute exposure of high-grade glioma 
cells to olaparib (3–5µM), an effect dramatically potentiated with 3Gy radi-
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